Upadacitinib is associated with sustained or improved responses across various patient-reported outcome measures at 140 weeks among those with AD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results